SE9604341D0 - Hepta-peptide oxytocin analogue - Google Patents

Hepta-peptide oxytocin analogue

Info

Publication number
SE9604341D0
SE9604341D0 SE9604341A SE9604341A SE9604341D0 SE 9604341 D0 SE9604341 D0 SE 9604341D0 SE 9604341 A SE9604341 A SE 9604341A SE 9604341 A SE9604341 A SE 9604341A SE 9604341 D0 SE9604341 D0 SE 9604341D0
Authority
SE
Sweden
Prior art keywords
pct
moiety
hepta
aminoacid
analogues
Prior art date
Application number
SE9604341A
Other languages
English (en)
Swedish (sv)
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Priority to SE9604341A priority Critical patent/SE9604341D0/xx
Publication of SE9604341D0 publication Critical patent/SE9604341D0/xx
Priority to BRPI9713366-3A priority patent/BR9713366B1/pt
Priority to NZ336445A priority patent/NZ336445A/en
Priority to PL97333876A priority patent/PL189292B1/pl
Priority to JP52460298A priority patent/JP3405460B2/ja
Priority to TR1999/01028T priority patent/TR199901028T2/xx
Priority to AU51429/98A priority patent/AU713424B2/en
Priority to RU99113364/04A priority patent/RU2180668C2/ru
Priority to CA002272990A priority patent/CA2272990C/en
Priority to HK00101422.6A priority patent/HK1022481B/xx
Priority to HU0000577A priority patent/HU228568B1/hu
Priority to RO99-00593A priority patent/RO120772B1/ro
Priority to CZ0183299A priority patent/CZ299532B6/cs
Priority to ZA9710518A priority patent/ZA9710518B/xx
Priority to AT97946210T priority patent/ATE242264T1/de
Priority to EP97946210A priority patent/EP0938496B1/en
Priority to CN97180014A priority patent/CN1129606C/zh
Priority to PCT/SE1997/001968 priority patent/WO1998023636A1/en
Priority to SK704-99A priority patent/SK283800B6/sk
Priority to PT97946210T priority patent/PT938496E/pt
Priority to IL12951997A priority patent/IL129519A/en
Priority to UA99042410A priority patent/UA54459C2/uk
Priority to KR10-1999-7004449A priority patent/KR100463132B1/ko
Priority to DE69722651T priority patent/DE69722651T2/de
Priority to US09/308,912 priority patent/US6143722A/en
Priority to HR970630A priority patent/HRP970630B1/xx
Priority to DK97946210T priority patent/DK0938496T3/da
Priority to EEP199900210A priority patent/EE03832B1/xx
Priority to SI9720076A priority patent/SI20026B/sl
Priority to ES97946210T priority patent/ES2203823T3/es
Priority to MYPI97005691A priority patent/MY125555A/en
Priority to ARP970105543A priority patent/AR008531A1/es
Priority to LVP-99-77A priority patent/LV12350B/en
Priority to LT99-052A priority patent/LT4650B/lt
Priority to NO19992532A priority patent/NO321380B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE9604341A 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue SE9604341D0 (sv)

Priority Applications (35)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
ES97946210T ES2203823T3 (es) 1996-11-26 1997-11-21 Analogos heptapeptidicos de oxitocina.
CN97180014A CN1129606C (zh) 1996-11-26 1997-11-21 七肽催产素类似物
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
PL97333876A PL189292B1 (pl) 1996-11-26 1997-11-21 Analog heptapeptydowy, środek farmacetyczny zawierający ten analog, zastosowanie analogu, zastosowanie środka farmacetycznego, sposób wytwarzania tego analogu oraz sposób wytwarzania środka farmacetycznego
JP52460298A JP3405460B2 (ja) 1996-11-26 1997-11-21 ヘプタペプチドオキシトシン類似体
TR1999/01028T TR199901028T2 (xx) 1996-11-26 1997-11-21 Heptapeptid oksitosin analoglar�.
AU51429/98A AU713424B2 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
RU99113364/04A RU2180668C2 (ru) 1996-11-26 1997-11-21 Гептапептидные аналоги окситоцина
CA002272990A CA2272990C (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
HK00101422.6A HK1022481B (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
HU0000577A HU228568B1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues pharmaceutical compositions containing them and their use and for producing them
PT97946210T PT938496E (pt) 1996-11-26 1997-11-21 Misturas insecticidas sinergicas
CZ0183299A CZ299532B6 (cs) 1996-11-26 1997-11-21 Heptapeptidový analog, farmaceutická kompozice obsahující tento analog, zpusob prípravy heptapeptidového analogu a jeho použití a zpusob prípravy farmaceutické kompozice obsahující tento analog
ZA9710518A ZA9710518B (en) 1996-11-26 1997-11-21 Oxytocin heptapeptide analogues.
AT97946210T ATE242264T1 (de) 1996-11-26 1997-11-21 Heptapeptid oxytocin analogen
EP97946210A EP0938496B1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
BRPI9713366-3A BR9713366B1 (pt) 1996-11-26 1997-11-21 análogos de heptapeptìdeo oxitocina.
SK704-99A SK283800B6 (sk) 1996-11-26 1997-11-21 Heptapeptidový analóg, farmaceutická kompozícia obsahujúca tento analóg, spôsob prípravy heptapeptidového analógu a jeho použitie pri príprave liečiva na redukciu alebo blokovanie kontrakcie maternicového svalu
NZ336445A NZ336445A (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
RO99-00593A RO120772B1 (ro) 1996-11-26 1997-11-21 Analogi de heptapeptidă, compoziţie farmaceutică care îi conţine şi procedeu de preparare a acestora
IL12951997A IL129519A (en) 1996-11-26 1997-11-21 Potateptide analogues with antagonistic activity to oxytocin, their preparation methods, pharmaceutical compositions containing them, and their use in the manufacture of drugs
UA99042410A UA54459C2 (uk) 1996-11-26 1997-11-21 Аналоги гептапептиду окситоцину, спосіб їх отримання, фармацевтична композиція, спосіб її отримання, спосіб запобігання передчасним пологам
KR10-1999-7004449A KR100463132B1 (ko) 1996-11-26 1997-11-21 헵타펩티드 옥시토신 동족체
DE69722651T DE69722651T2 (de) 1996-11-26 1997-11-21 Heptapeptid oxytocin analogen
US09/308,912 US6143722A (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues
HR970630A HRP970630B1 (en) 1996-11-26 1997-11-21 Hepapeptide oxytocin analogues
DK97946210T DK0938496T3 (da) 1996-11-26 1997-11-21 Heptapeptidoxytocinanaloger
EEP199900210A EE03832B1 (et) 1996-11-26 1997-11-21 Heptapeptiidanaloogid
SI9720076A SI20026B (sl) 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina
MYPI97005691A MY125555A (en) 1996-11-26 1997-11-25 Heptapeptide oxytocin analogues
ARP970105543A AR008531A1 (es) 1996-11-26 1997-11-26 Análogos a heptapeptidos antagonistas de la oxitocina
LVP-99-77A LV12350B (en) 1996-11-26 1999-04-30 HEPTAPEPHITE OXITOCIN ANALOGUE
LT99-052A LT4650B (lt) 1996-11-26 1999-05-11 Heptapeptidiniai oksitocino analogai
NO19992532A NO321380B1 (no) 1996-11-26 1999-05-26 Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue

Publications (1)

Publication Number Publication Date
SE9604341D0 true SE9604341D0 (sv) 1996-11-26

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue

Country Status (34)

Country Link
US (1) US6143722A (da)
EP (1) EP0938496B1 (da)
JP (1) JP3405460B2 (da)
KR (1) KR100463132B1 (da)
CN (1) CN1129606C (da)
AR (1) AR008531A1 (da)
AT (1) ATE242264T1 (da)
AU (1) AU713424B2 (da)
BR (1) BR9713366B1 (da)
CA (1) CA2272990C (da)
CZ (1) CZ299532B6 (da)
DE (1) DE69722651T2 (da)
DK (1) DK0938496T3 (da)
EE (1) EE03832B1 (da)
ES (1) ES2203823T3 (da)
HR (1) HRP970630B1 (da)
HU (1) HU228568B1 (da)
IL (1) IL129519A (da)
LT (1) LT4650B (da)
LV (1) LV12350B (da)
MY (1) MY125555A (da)
NO (1) NO321380B1 (da)
NZ (1) NZ336445A (da)
PL (1) PL189292B1 (da)
PT (1) PT938496E (da)
RO (1) RO120772B1 (da)
RU (1) RU2180668C2 (da)
SE (1) SE9604341D0 (da)
SI (1) SI20026B (da)
SK (1) SK283800B6 (da)
TR (1) TR199901028T2 (da)
UA (1) UA54459C2 (da)
WO (1) WO1998023636A1 (da)
ZA (1) ZA9710518B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
WO2003072597A1 (en) * 2002-02-27 2003-09-04 Ferring Bv Intermediates and methods for making heptapeptide oxytocin analogues
EP1504268A2 (en) * 2002-05-02 2005-02-09 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
ATE301990T1 (de) * 2003-07-25 2005-09-15 Ferring Bv Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
EP1530967B1 (en) * 2003-11-13 2006-05-03 Ferring B.V. Blister pack and solid dosage form comprising desmopressin
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
AU2008283929B2 (en) 2007-08-06 2013-10-10 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
DK2260053T3 (da) * 2008-03-31 2014-06-23 Ferring Bv Oxytocin-analoger
PL2712622T3 (pl) 2008-05-21 2017-01-31 Ferring B.V. Ulegająca rozpadowi w ustach desmopresyna do zwiększania początkowego okresu snu niezakłócanego przez nokturię
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
JP6150726B2 (ja) 2011-03-09 2017-06-21 Jitsubo株式会社 新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CA3001057A1 (en) 2015-10-06 2017-04-13 Ferring B.V. New methods for making barusiban and its intermediates
CA3009576A1 (en) 2016-01-04 2017-07-13 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
UA127283C2 (uk) 2016-07-21 2023-07-12 Обсева С.А. Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL155712B1 (en) * 1987-12-21 1991-12-31 Sandoz Ag Method of obtaining novel crystalline form of cyclosporin
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
DE4022247A1 (de) * 1990-07-12 1992-01-16 Hoechst Ag Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE503085C2 (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
LV12350B (en) 1999-11-20
DK0938496T3 (da) 2003-10-06
US6143722A (en) 2000-11-07
IL129519A0 (en) 2000-02-29
ZA9710518B (en) 1998-06-10
PT938496E (pt) 2003-10-31
SK70499A3 (en) 2000-10-09
UA54459C2 (uk) 2003-03-17
ATE242264T1 (de) 2003-06-15
CA2272990A1 (en) 1998-06-04
MY125555A (en) 2006-08-30
AR008531A1 (es) 2000-01-19
JP3405460B2 (ja) 2003-05-12
HU228568B1 (en) 2013-04-29
NO992532D0 (no) 1999-05-26
LT4650B (lt) 2000-04-25
CA2272990C (en) 2002-11-19
HUP0000577A3 (en) 2001-02-28
EE03832B1 (et) 2002-08-15
KR20000069045A (ko) 2000-11-25
BR9713366A (pt) 2000-01-25
EP0938496A1 (en) 1999-09-01
ES2203823T3 (es) 2004-04-16
NO992532L (no) 1999-05-26
RU2180668C2 (ru) 2002-03-20
SK283800B6 (sk) 2004-02-03
JP2000507617A (ja) 2000-06-20
WO1998023636A1 (en) 1998-06-04
SI20026B (sl) 2000-06-30
SI20026A (sl) 2000-02-29
BR9713366B1 (pt) 2010-05-18
TR199901028T2 (xx) 1999-07-21
HRP970630B1 (en) 2002-04-30
HRP970630A2 (en) 1998-10-31
CZ299532B6 (cs) 2008-08-27
LT99052A (en) 2000-01-25
DE69722651D1 (en) 2003-07-10
AU5142998A (en) 1998-06-22
HK1022481A1 (en) 2000-08-11
DE69722651T2 (de) 2004-04-08
EP0938496B1 (en) 2003-06-04
IL129519A (en) 2004-09-27
RO120772B1 (ro) 2006-07-28
LV12350A (lv) 1999-09-20
AU713424B2 (en) 1999-12-02
HUP0000577A2 (hu) 2000-11-28
KR100463132B1 (ko) 2004-12-23
EE9900210A (et) 1999-12-15
CZ183299A3 (cs) 2000-05-17
NZ336445A (en) 2000-06-23
CN1129606C (zh) 2003-12-03
CN1238781A (zh) 1999-12-15
PL189292B1 (pl) 2005-07-29
NO321380B1 (no) 2006-05-02

Similar Documents

Publication Publication Date Title
SE9604341D0 (sv) Hepta-peptide oxytocin analogue
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
TW363064B (en) Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
HUP9901209A2 (hu) Opioid analóg peptid vegyületek, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
MC2326A1 (fr) Antagonistes d'un nonapeptide de la bombesine
DE69723728D1 (de) Totalsynthese des amino hip analogen von didemnin a
NO944293L (no) Bombesin antagonist-polypeptider
DE69630699D1 (de) Heterocyclische verbindungen als bradykinin antagonisten
MX9201055A (es) N-[[4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il] carbonil] aminoacidos utiles en la terapia de afecciones osteoarticulares.
DE69119409D1 (de) Vasoaktive derivate des vasotocins
SE9800865D0 (sv) New Process
BR0113671A (pt) Antagonistas de integrina alfa v beta 3 gem-substituìda
Natarajan et al. Ketomethylureas. A new class of angiotensin converting enzyme inhibitors